Abstract

BARJA LOPEZ, Juan Manuel. Epidemic Kaposi sarcoma in Sub-Saharan Africa. Rev Cubana Med Trop [online]. 2019, vol.71, n.1, e311.  Epub June 30, 2019. ISSN 0375-0760.

Kaposi sarcoma (KS) has become one of the most prevalent tumors in Africa after the HIV epidemic. KS affects both men and women. Diagnostic delay and limited access to antiretroviral treatment or chemotherapy have an impact on the prognosis of KS patients. A review was conducted about KS with the purpose of describing its most outstanding characteristics in recent years in Africa, such as its epidemiology, clinical features, and existing therapeutic options. This tumor is caused by infection with human herpesvirus 8, which is more prevalent in rural areas of the African continent. Transmission via saliva was found to be the most important transmission route in Africa. HIV-related immunosuppression fosters the oncogenic effect of the virus. The epidemic form of KS initially presents as hyperpigmented or violet-colored skin lesions which may extend to lymph nodes or mucosae, or systemically, mainly to the lungs or the digestive tract. Systemic immune reconstitution syndrome may complicate the patient's evolution. Early start of antiretroviral therapy is indispensable. Additionally, prognosis improves with chemotherapy with doxorubicin, vincristine, etoposide or bleomycin, mainly.

Keywords : Kaposi sarcoma; human herpesvirus 8; Africa; human immunodeficiency virus.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )